We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




HPV, p16 Offers Different Prognostic Clues in Oropharyngeal Cancer

By LabMedica International staff writers
Posted on 07 Oct 2020
Print article
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Image: Photomicrograph of histology of a poorly differentiated squamous cell carcinoma (SCC) that is p16 positive (Photo courtesy of Nephron).
Human papillomavirus infection (HPV infection) is an infection caused by human papillomavirus (HPV), a DNA virus from the Papillomaviridae family. About 90% of HPV infections cause no symptoms and resolve spontaneously within two years.

Human papillomavirus-positive oropharyngeal cancer (HPV-positive OPC or HPV+OPC), is a squamous cell carcinoma of the throat caused by the human papillomavirus type 16 virus. Detection of a tumor suppressor protein, known as p16, is commonly used to diagnose an HPV associated OPC.

Oncologists at the Catalan Institute of Oncology (Barcelona, Spain) retrospectively analyze clinical features and outcomes in relation to p16 and HPV status in more than 7,700 individuals with oropharyngeal cancer enrolled in 13 cohorts from sites in nine European or North American countries. HPV and p16 were measured by immunohistochemistry (IHC) and the HPV DNA in situ hybridization (ISH) assay, respectively which can identify clusters of oropharyngeal cancers that appear to be at intermediate risk of recurrence or death compared to tumors that are p16-positive and HPV-positive and those lacking both markers.

IHC profiling is a sensitive approach for picking up p16, a surrogated marker for HPV, albeit with reduced specificity, since that host protein sometimes has enhanced expression even in the absence of HPV infection. On the other hand, the DNA ISH test is less sensitive, since it depends to some extent on the viral load, though it is also far more specific for finding risky HPV strains. Based on analyses done at a centralized site, the team classified 416 cases as p16-positive and HPV-negative, while 279 individuals with oropharyngeal cancer had p16-negative tumors testing positive for HPV by DNA ISH. The remaining patients included 3,598 with p16-negative and HPV-negative tumors and 3,409 cases classified as positive for both markers.

Nearly 90% of the p16-negative, HPV-negative cancers occurred in smokers, compared to a smoking rate of 62% in the patients with p16-positive, HPV-positive tumors. Notably, the cases showing discordant p16 and HPV marker status had smoking history in between these two groups. The team also saw a range of treatment interventions, including an uptick in surgeries and palliative care in the p16- and HPV-negative cases, followed by cases with HPV but not p16. When the investigators looked at overall survival in the biomarker-defined groups of stage III or IVa/b, locally advanced oropharyngeal cancer cases, they found that significantly more patients with p16- and HPV-positive tumors were alive after five years, whereas outcomes were more dire for the p16- and HPV-negative cases.

Miren Taberna, MD, a clinical oncologist and senior author of the study, said, “Using p16 staining alone, 11% of oropharyngeal cancer patients would be incorrectly classified as HPV-related, suggesting incorrect prognostic conclusions could be drawn from p16 testing alone, which would potentially place these patients in a de-escalation group inappropriately.” The study was presented at the European Society for Medical Oncology's Virtual Congress held in September 2020.

Related Links:
Catalan Institute of Oncology

Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total Thyroxine Assay
Total Thyroxine CLIA Kit
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.